FOX 04 5MG

FOX04-DRI 

Chemical Name: FOXO4-D-Retro-Inverso Peptide
Chemical Formula: Varies depending on the sequence of amino acids.
Molecular Weight: Varies depending on formulation, but typically within the range of ~6000-8000 Da.

FOX04-DRI is a modified peptide designed to target and inhibit the activity of the FOXO4 transcription factor, which is involved in cellular aging processes. Specifically, FOXO4-DRI interacts with p53, a critical protein in the regulation of the cell cycle and apoptosis (programmed cell death). By disrupting the interaction between FOXO4 and p53, FOX04-DRI selectively induces the death of senescent cells—cells that have stopped dividing but are not dead—which are implicated in aging and age-related diseases. This makes FOX04-DRI a key subject in anti-aging research and therapies aimed at promoting healthy aging and longevity.

Mechanism of Action

The FOXO4 transcription factor plays a crucial role in cellular stress responses, including regulating the decision of whether damaged cells undergo apoptosis or survive in a senescent state. In senescent cells, FOXO4 binds to p53, preventing it from inducing apoptosis.

FOX04-DRI (D-Retro-Inverso isomer) is a stabilized version of the peptide that disrupts this interaction, freeing p53 to trigger apoptosis specifically in senescent cells, while sparing healthy, functional cells. This selective clearing of senescent cells has potential implications in reducing the burden of aging cells that contribute to tissue dysfunction, inflammation, and various age-related diseases.

Top 7 Research Benefits of FOX04-DRI

• Senolytic Activity (Clearing Senescent Cells): FOX04-DRI is classified as a senolytic, meaning it selectively induces the death of senescent cells without harming healthy cells. This has profound implications in research focused on age-related tissue dysfunction, as the accumulation of senescent cells is a major driver of aging and degenerative diseases.

• Potential Anti-Aging Properties: By clearing senescent cells, FOX04-DRI may reduce age-related tissue damage, improve organ function, and promote healthier aging. Researchers are particularly interested in its potential to extend lifespan and enhance healthspan—the period of life spent in good health.

• Reduction of Inflammation: Senescent cells are known to secrete pro-inflammatory factors, a phenomenon known as the Senescence-Associated Secretory Phenotype (SASP). By reducing the number of senescent cells, FOX04-DRI may decrease chronic inflammation, which is a hallmark of aging and is implicated in many age-related diseases, including cardiovascular diseases and neurodegeneration.

• Improved Tissue Function and Regeneration: Research has shown that clearing senescent cells can improve the regenerative capacity of tissues. FOX04-DRI may promote better tissue repair and regeneration, making it a focus in studies involving conditions like fibrosis, muscle degeneration, and skin aging.

• Neuroprotective Potential: Senescent cells contribute to the aging of the brain and neurodegenerative diseases like Alzheimer’s and Parkinson’s. FOX04-DRI is being explored for its potential to clear senescent cells in the brain, which may help protect neurons, reduce neuroinflammation, and improve cognitive function in age-related cognitive decline.

• Potential in Cancer Research: The FOXO4-p53 interaction also plays a role in cancer development. While FOXO4-DRI’s primary focus is anti-aging, researchers are investigating its potential as an adjunct in cancer research, particularly in cancers where the accumulation of senescent cells or dysfunctional p53 is a factor.

• Improved Metabolic Health: FOX04-DRI may help improve metabolic function by reducing the presence of senescent cells in fat tissue, liver, and other organs. This is particularly important in research related to metabolic syndrome, type 2 diabetes, and obesity, which are all exacerbated by chronic inflammation and cellular senescence.

Dosing Information for Research Purposes

In research settings, FOX04-DRI is administered via injection, usually subcutaneously or intraperitoneally, depending on the study model. Dosing protocols vary based on the model used and the specific goals of the study.

• Typical Research Dosing:
  In preclinical models, doses of 5 mg/kg to 10 mg/kg have been explored, with treatment periods ranging from several weeks to observe the effects of senescent cell clearance on tissue function, inflammation, and overall health outcomes.

Research Safety and Considerations

While FOX04-DRI has shown promise in early-stage research, its effects in humans are not yet fully understood. Researchers must carefully monitor for potential side effects, especially since clearing senescent cells may have unanticipated consequences in long-term studies.

• Potential Side Effects:
  So far, animal studies have indicated that FOX04-DRI is relatively well-tolerated, but researchers should watch for signs of unwanted apoptosis in non-senescent cells, which could lead to tissue damage or impaired function.
• Long-Term Impact:
  More research is needed to determine the long-term effects of senolytic therapies like FOX04-DRI, particularly on immune function and tissue regeneration, where senescent cells may play complex roles.

Researchers are particularly interested in determining whether intermittent dosing of FOX04-DRI can clear senescent cells without causing negative impacts on overall tissue homeostasis and whether it can be used alongside other anti-aging interventions.

Conclusion

FOX04-DRI is a cutting-edge peptide in the field of senolytic research, offering a novel approach to reducing the burden of senescent cells, which contribute to aging, inflammation, and various age-related diseases. With its ability to selectively induce apoptosis in damaged cells, FOX04-DRI has significant potential in anti-aging, neuroprotection, tissue regeneration, and metabolic research.

Disclaimer: FOX04-DRI is intended for research purposes only and is not approved for human use outside of regulated research environments. All research involving FOX04-DRI must comply with relevant legal and ethical guidelines.